Eleven Biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. Eleven Biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the Company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders.  Eleven Biotherapeutics is a Flagship VentureLabs company.

Noubar Afeyan and David Berry are on the Board of Directors.